Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
EZH2 inhibitor
Tazemetostat
Tazverik · TAZ
First-in-class EZH2 inhibitor with a generally low direct renal toxicity — the kidney-relevant concern is treatment-related tumor lysis in lymphoma.
MildEpigenetic (EZH2) era · approved 2020
Relapsed/refractory follicular lymphoma (EZH2-mutant after >=2 prior therapies, or no satisfactory alternatives)Metastatic or unresectable epithelioid sarcoma not eligible for complete resection
Signature kidney injury
Prerenal / Hemodynamic AKI
Tazemetostat is generally well tolerated with low direct organ toxicity; the noted boxed risk is secondary T-cell lymphoma/myeloid malignancy. Tumor lysis is an uncommon, treatment-related concern in responding lymphoma. A discrete AKI rate is not quantified and direct nephrotoxicity is low.
Source: Morschhauser et al., Lancet Oncol 2020 (follicular lymphoma); Gounder et al., Lancet Oncol 2020 (epithelioid sarcoma)
Mechanism of kidney injury
Tazemetostat has no characteristic direct renal lesion. Its renal relevance is limited and indirect: in responding lymphoma, cytoreduction can release uric acid, phosphate and potassium, producing tumor-lysis crystalline nephropathy (urate and calcium-phosphate intratubular precipitation) and ATN; gastrointestinal toxicity and reduced intake can cause prerenal volume depletion. The epigenetic mechanism itself is not nephrotoxic.
Clinical presentation
Generally mild fatigue, nausea and musculoskeletal symptoms; when tumor lysis occurs, hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia and AKI early after a brisk response. Prerenal azotemia with poor intake.
Onset
Tumor lysis, if it occurs, is early after response; prerenal effects track intercurrent GI toxicity.
Reversibility
Reversible
Anticancer mechanism
Oral selective inhibitor of EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2) that trimethylates histone H3 lysine 27 (H3K27me3). Inhibition reverses aberrant gene silencing in EZH2-mutant follicular lymphoma and in INI1/SMARCB1-deficient epithelioid sarcoma.
Management
Treat tumor lysis with aggressive IV hydration, urate-lowering therapy (rasburicase for high uric acid), electrolyte correction and renal replacement if refractory. Restore volume for prerenal AKI. Given low intrinsic toxicity, routine dosing rarely needs renal-driven modification; renal events are generally reversible.
Risk factors
- High tumor burden/bulky lymphoma (tumor-lysis risk)
- Pre-existing CKD and concurrent nephrotoxins
- Volume depletion from GI toxicity
- Hyperuricemia at baseline
Prevention
- Tumor-lysis risk assessment with hydration +/- allopurinol or rasburicase in higher-risk lymphoma
- Maintain hydration; manage GI toxicity
- Monitor renal function and electrolytes early in responders
- Avoid additive nephrotoxins
Note · The renal link is indirect and uncommon — chiefly treatment-related tumor lysis in responding lymphoma and prerenal volume depletion; direct nephrotoxicity is low. No taz-specific TLS/renal paper exists, so TLS/onconephrology consensus is cited.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment defined for mild-moderate impairment; severe impairment/ESKD not characterized (hepatic CYP3A metabolism). Modifications relate to hematologic toxicity and the secondary-malignancy risk.
Dialyzability & ESKD dosing
Highly protein-bound; not expected to be dialyzable. Dialysis is used for TLS metabolic complications, not drug removal.
Differential diagnosis
Distinguish tumor-lysis crystalline nephropathy (early hyperuricemia/hyperphosphatemia in responders) from prerenal azotemia and other AKI causes. The agent's low intrinsic toxicity makes a primary drug nephropathy unlikely.
Monitoring
- Serum creatinine, uric acid, phosphate and potassium early in responders (TLS surveillance)
- CBC per schedule (and surveillance for secondary malignancy)
- Volume status with GI toxicity
- Electrolytes periodically
Key trials & series
- Morschhauser et al. (Lancet Oncol 2020) — registrational follicular lymphoma cohort
- Gounder et al. (Lancet Oncol 2020) — epithelioid sarcoma cohort
Clinical pearls
- Tazemetostat is generally well tolerated; the kidney-relevant concern is tumor lysis in responding lymphoma, not the drug itself.
- Risk-stratify bulky lymphoma for TLS and pre-treat with hydration +/- rasburicase.
- Remember the boxed secondary-malignancy risk when counseling and on long-term follow-up.
- No tazemetostat-specific renal lesion is described.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Tubular Lumen
The urine flow path
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkTazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.Morschhauser F et al. · Lancet Oncol 2020 · PMID 33035457Registrational follicular lymphoma cohort defining efficacy and the favorable tolerability profile.PMIDTazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.Gounder M et al. · Lancet Oncol 2020 · PMID 33035459Epithelioid sarcoma cohort confirming the low direct-toxicity profile.PMIDTazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.Italiano A et al. · Lancet Oncol 2018 · PMID 29650362First-in-human safety/pharmacology establishing tolerability.PMIDTazemetostat: a review in relapsed or refractory follicular lymphoma.Julia E et al. · Future Oncol 2021 · PMID 33709777Clinical review summarizing efficacy and adverse-event management.PMIDGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.Cairo MS et al. · J Clin Oncol 2010 · PMID 20331465Consensus TLS prophylaxis/management applicable to responding lymphoma.PMIDOnconephrology: The Intersections Between the Kidney and Cancer.Rosner MH et al. · CA Cancer J Clin 2021 · PMID 32998135Framework for tumor-lysis and secondary AKI in hematologic malignancy.
Related agents
Other agents sharing the same signature kidney injury.